Carbetocin Versus Misoprostol. A Retrospective Comparative Study
NCT ID: NCT04313218
Last Updated: 2020-03-18
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
300 participants
OBSERVATIONAL
2018-01-01
2020-02-28
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Efficacy of Carbetocin Versus Oxytocin Plus Misoprostol in Decreasing Blood Loss During Cesarean Section
NCT05664659
Carbetocin Versus Misoprostol in High Risk Patients for Postpartum Hemorrhage After C.S.
NCT02277067
Intrauterine Misoprostol Versus Intravenous Oxytocin Infusion During Cesarean Delivery
NCT03148574
Carbetocin Versus Buccal Misoprostol Plus IV Tranexamic Acid for Prevention of Postpartum Hemorrhage at Cesarean Section
NCT03710317
Carbetocin Versus Misoprostol in Cases With Placenta Previa After C.S.
NCT02277041
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Carbetocin is an oxytocin analogue containing eight amino acids .It binds to oxytocin receptors expressed on uterine muscles of pregnant women inducing tetanic uterine contractions for about 11 minutes after administration of 8-30ug intravenous followed by rhythmic uterine contractions that last for 60 to 120 minutes. Also it has a longer half life time than oxytocin and the recommended dose is 100ug IV.
Misoprostol is synthetic analogue to prostaglandin which is cheap heat stable uterotonic making it the alternative of choice to intravenous oxytocin in low resources countries. The recommended dose for prophylaxis against postpartum hemorrhage is 600μg while 800μg is used as a treatment.
In the lack of sufficient studies comparing the use of carbetocin to misoprostol to decrease blood loss during cesarean section we perform this study to compare the use of misoprostol to carbetocin in reducing blood loss during cesarean section.
Patients and Methods This was a retrospective comparative study conducted in Port Said General Hospital And Private practice in Port Said Egypt. Following approval of the study protocol by the ethical committee in Faculty of medicine Port Said University. The medical records of patients in the period from January 2018 to February 2019 were searched; women who underwent CS and were considered at low risk for postpartum including 1- singleton pregnancy, 2- less than previous four deliveries, 3- elective lower segment C.S, 4- C.S was done under general anesthesia 5- No medical disorders complicating pregnancy, 6- Placenta neither previa nor morbidly adherent, 7- Average amount of amniotic fluid, 8- No past history of postpartum hemorrhage and 9- No contraindications to Misopristol or Carbetocin 300 patients were eligible and were enrolled in this study. Women who received Carbetocin 100ug i.v (PABAL 100 micrograms/ml solution for injection, Ferring Pharmaceuticals Ltd) intra operative immediately after extraction of the fetus, were enrolled into group A and women who received misoprostol 600ug (cytotec 200ug tablet, Pfizer G.D. Searle LLC) rectally immediately before sterilization during caesarean section were enrolled into group B.
Maternal data (demographic and clinical), ultrasound findings, operative details, and postoperative characteristics were recorded in a database. The outcome measures of this study were the need for blood products transfusion, the amount of blood products transfusion, the operative time, operative complications uterine atony the need for surgical interventions to stop bleeding as uterine artery ligation and uterine compression sutures and the deficit in hemoglobin level.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
OTHER
RETROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
A
recieved carbetocin 100ug iv after immediately after extraction of the fetus during cesarean section
Carbetocin
iv infusion of 100ug carbetocin after extraction of the fetus during cesarean section
B
women who received misoprostol 600ug rectally immediately before sterilization during cesarean section
No interventions assigned to this group
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Carbetocin
iv infusion of 100ug carbetocin after extraction of the fetus during cesarean section
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* unscarred uterus or previous one cesarean section
* elective C.S
* general anesthesia
Exclusion Criteria
* more than one C.S
* selective C.S
* Risk factors for Postpartum hemorrhage
FEMALE
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Port Said University hospital
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
waleed elsayed elrefaie
Assistant professor
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Waleed Elsayed Elrefaie
Port Said, NY, Egypt
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
OBSGYN 1
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.